Trial reportAddiction biology2026
A Membrane-Centric Plasma Lipidomic Signature of Response to Long-Acting Naltrexone in Alcohol Use Disorder.
Trial report in Addiction biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Long-acting naltrexone is a first-line pharmacotherapy for alcohol use disorder (AUD), but clinical response is heterogeneous and the underlying biology remains incompletely understood. In a randomised, double-blind, placebo-controlled trial of naltrexone implants (n = 70), the prespecified primary endpoint-percentage of heavy-drinking days (PHDD) over 24 weeks-favoured naltrexone (median 1.49% vs. 13.39%; p = 0.042). In a prespecified Week-12 mechanistic lipidomics substudy, untargeted liquid chromatography-mass spectrometry (LC-MS) profiling was performed in a responder-enriched subset comprising naltrexone responders (RN, n = 18), placebo-treated participants (PL, n = 10) and age- and BMI-matched healthy male controls (HC, n = 10). We derived membrane-related indices reflecting two prespecified axes of phospholipid remodelling: headgroup balance (PC/PE) and acyl-chain composition (arachidonic acid [AA] and n-3 polyunsaturated fatty acids within phospholipid pools). RN showed higher PC/PE and coordinated acyl-chain shifts versus PL, with species-level changes preferentially moving toward the healthy-control direction. Exploratory analyses in naltrexone nonresponders (NR, n = 10) revealed partial Lands-cycle-related shifts but lacked the broader dual-axis configuration observed in RN. In RN + PL (n = 28), higher n-3 in PE and lower AA in PE at Week 12 were prospectively associated with greater subsequent heavy-drinking burden. These findings support a dual-axis membrane remodelling phenotype associated with naltrexone response and prospectively linked to heavy-drinking burden in AUD, providing a biologically grounded framework for future mechanistic and biomarker studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.